Letter to the EditorEffective treatment of restless legs syndrome by safinamide in Parkinson's disease patients
Section snippets
Authors contributions
Claudio Liguori: cases concept, acquisition of data, data analysis and interpretation, drafting the manuscript.
Alessandro Stefani: critical revision of the manuscript for important intellectual content.
Nicola Biagio Mercuri: critical revision of the manuscript for important intellectual content.
Mariangela Pierantozzi: cases concept and supervision, data analysis and interpretation.
Claudio Liguori, Nicola Biagio Mercuri, Alessandro Stefani and Mariangela Pierantozzi declare no conflict of
References (7)
- et al.
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Lancet Neurol
(2009 May) - et al.
Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation
Sleep Med
(2016 May) - et al.
Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria–history, rationale, description, and significance
Sleep Med
(2014 Aug)
Cited by (17)
Special considerations for treatment of sleep-related movement disorders
2023, Encyclopedia of Sleep and Circadian Rhythms: Volume 1-6, Second EditionEffects of safinamide on REM sleep behavior disorder in Parkinson disease: A randomized, longitudinal, cross-over pilot study
2021, Journal of Clinical NeuroscienceCitation Excerpt :Whereas Kumru et al. reported that pramipexole did not modify RBD related symptoms or vPSG abnormalities in PD patients [21]. Recently two small studies have tested the effect of safinamide on subjective sleep [22,23]. Our study reports for the first time that safinamide showed a favorable effects on RBD-symptoms.
Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study
2018, Parkinsonism and Related DisordersEffectiveness and safety of safinamide in the Toledo Movement Disorders Unit
2023, Revista de NeurologiaMonoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkin-son’s Disease: Beyond the Primary Mechanism of Action
2023, Current NeuropharmacologyNon-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study
2022, Journal of Neural Transmission